Akebia Therapeutics (AKBA) Enterprise Value (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Enterprise Value of -$162.6 million for Q1 2026, down 43.39% year-over-year from -$287.2 million in Q1 2025, and up 12.03% quarter-over-quarter from -$184.8 million in Q4 2025.
Akebia Therapeutics (AKBA) Enterprise Value (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Enterprise Value for 14 consecutive years, with -$162.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 43.39% year-over-year to -$162.6 million; the TTM figure through Mar 2026 stood at -$162.6 million (down 43.39% YoY), while the FY2025 annual figure was -$184.8 million, down 256.36% from the prior year.
- Enterprise Value improved to -$162.6 million in Q1 2026 per AKBA's latest filing, from -$184.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$34.0 million in Q3 2024 and bottomed at -$184.8 million in Q4 2025.
- Historically, Enterprise Value has averaged -$99.2 million across 5 years, with a median of -$90.5 million in 2022.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 67.86% — and 2025, when it tumbled 389.54%.
- Akebia Therapeutics' Enterprise Value stood at -$90.5 million in 2022, then jumped by 52.55% to -$42.9 million in 2023, then slipped by 20.84% to -$51.9 million in 2024, then slumped by 256.36% to -$184.8 million in 2025, then grew by 12.03% to -$162.6 million in 2026.
- Business Quant data shows AKBA's Enterprise Value at -$162.6 million in Q1 2026, -$184.8 million in Q4 2025, and -$166.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -164.00 Mn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | -155.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -155.55 Mn |
| Mar 31, 2026 | -162.60 Mn |
| Dec 31, 2025 | -184.84 Mn |
| Sep 30, 2025 | -166.44 Mn |
| Jun 30, 2025 | -137.31 Mn |
| Mar 31, 2025 | -113.40 Mn |
| Dec 31, 2024 | -51.87 Mn |
| Sep 30, 2024 | -34.00 Mn |
| Jun 30, 2024 | -39.50 Mn |
| Mar 31, 2024 | -42.00 Mn |
| Dec 31, 2023 | -42.93 Mn |
| Sep 30, 2023 | -46.53 Mn |
| Jun 30, 2023 | -53.57 Mn |
| Mar 31, 2023 | -57.00 Mn |
| Dec 31, 2022 | -90.47 Mn |
| Sep 30, 2022 | -144.76 Mn |
| Jun 30, 2022 | -143.90 Mn |
| Mar 31, 2022 | -174.60 Mn |
| Dec 31, 2021 | -149.80 Mn |
| Sep 30, 2021 | -207.20 Mn |